Doctor unpacks FDA's removal of "black box" warnings on some menopause hormone therapies

Key Concepts

Menopause/Perimenopause: Transitional phases in a woman's life marked by hormonal changes.
Hormone Therapy (HT): Medical treatment involving the administration of hormones, primarily estrogen and progestin, to alleviate menopausal symptoms.
Black Box Warning: The strongest warning issued by the FDA, indicating serious or life-threatening risks associated with a drug.
FDA (Food and Drug Administration): The U.S. regulatory agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, etc.
Estrogen: A primary female sex hormone.
Progestin: A synthetic form of progesterone, another female sex hormone.
Endometrial Cancer: Cancer of the lining of the uterus.
Osteoporosis: A condition characterized by weakened bones, making them more susceptible to fractures.
Vasomotor Symptoms: Symptoms related to the regulation of blood vessels, commonly manifesting as hot flashes and night sweats.
Cognitive Symptoms: Symptoms affecting mental processes, such as "brain fog."
Cardiovascular Disease: Diseases affecting the heart and blood vessels.
Breast Cancer: Cancer that develops in the breast tissue.
Stroke: A medical emergency that occurs when the blood supply to part of the brain is interrupted or reduced, preventing brain tissue from getting oxygen and nutrients.
Women's Health Initiative (WHI) Study: A large-scale research program that provided significant data on women's health, including the risks and benefits of hormone therapy.
Bioidentical Estradiol: A type of estrogen that is chemically identical to the estrogen produced by the human body.
Conjugated Equine Estrogen: A type of estrogen derived from pregnant mares.

FDA's Decision to Remove Black Box Warnings on Hormone Therapy

The U.S. Food and Drug Administration (FDA) has announced a significant policy change: the removal of black box warning labels from many hormone therapy (HT) drugs. This decision is described by the FDA Commissioner as ending "a decades-long fear machine" and is being called "one of the biggest mistakes in modern medicine" and an "American tragedy." This change is expected to encourage more of the tens of millions of American women experiencing menopause or perimenopause to seek treatment for their symptoms.

Initial Reactions and the Scope of the Change

Dr. Tammy Rohan, Associate Professor at the University of California, San Francisco, expressed pleasant surprise at the FDA's decision. While she and many medical societies had advocated for years for the removal of black box warnings on vaginal estrogen, the broader removal of these warnings on all estrogen products was unexpected.

Seeking Treatment and Access to Care

For women hearing this news and wanting to seek treatment, Dr. Rohan advises consulting with a doctor to determine an appropriate regimen. She acknowledges that specialized menopause treatment providers may not be readily available in all areas, especially outside of major cities. However, she reassures that many healthcare professionals, including OB/GYNs, physician's assistants, and nurse practitioners, have been prescribing menopausal hormone therapy for years, even with the black box warnings. These providers have had to explain the warnings and their understanding of the evidence to patients.

Dr. Rohan suggests looking locally for providers who are comfortable prescribing HT and are evidence-based. She also highlights the availability of nationally certified practitioners through The Menopause Society and telehealth companies that can provide care under good guidance. The increasing interest among providers in this field is a positive development, with many dedicating time to educating others on the science, safety, and prescription of HT, as this was not extensively covered in traditional medical training.

Additional Benefits of Hormone Therapy Beyond Symptom Relief

Beyond addressing menopausal symptoms, HT offers significant additional benefits. A primary concern historically has been the safety of HT regarding cardiovascular disease, breast cancer, and stroke.

Breast Cancer: Data suggests that estrogen, particularly specific types like conjugated equine estrogen when taken alone, does not cause breast cancer. In fact, the Women's Health Initiative (WHI) study indicated that this specific type of estrogen reduces the risk of breast cancer.
Endometrial Cancer: The concern that estrogen alone can increase the risk of endometrial (uterine) cancer is addressed by co-prescribing it with a progestin. The nuance in risk management lies in this combination therapy.
Osteoporosis: HT is unequivocally beneficial and FDA-approved for preventing osteoporosis. This is a critical benefit for women, as hip fractures, often a consequence of osteoporosis, are a leading cause of mortality in older women.
Cognitive Symptoms: While randomized controlled trial data does not strongly support the prevention of Alzheimer's disease, many women report subjective benefits in terms of cognitive symptoms like "brain fog."
Vasomotor Symptoms: Hot flashes and night sweats, which are also markers of cardiovascular disease, significantly improve with HT.
Cardiovascular Health: There is some data suggesting potential cardiovascular benefits from these medications.

Conclusion

The FDA's decision to remove black box warnings on many hormone therapy drugs marks a significant shift in the medical understanding and approach to menopausal symptom management. This change aims to alleviate decades of fear and encourage more women to seek effective treatment. While access to specialized care is a consideration, a growing number of healthcare providers are becoming proficient in prescribing HT, and various avenues, including telehealth, are available. The evidence now strongly supports the safety and efficacy of HT, not only for symptom relief but also for crucial benefits like osteoporosis prevention and potential improvements in cognitive and cardiovascular health.